Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease
JCC Plus · 2026-05 · 1 (3)
DOI: 10.1002/jcc5.70040 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCC Plus, online erschienen am 21.05.2026. Verfasst von Nicole M. Garcia und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Upadacitinib is a selective Janus kinase 1 inhibitor that has demonstrated rapid onset and efficacy in patients with moderate‐to‐severe Crohn's disease (CD) and ulcerative colitis (UC). Here, we describe the real‐world efficacy and safety of upadacitinib in combination with biologic therapies for IBD.
Methods
We performed a single center retrospective study of patients with moderate‐to‐severe IBD on upadacitinib in combination with biologic therapy from August 2020 to August 2024. The primary outcome was clinical response and remission at weeks 8, 28, and 52. Secondary outcomes include endoscopic response and remission, intestinal ultrasound response, and biomarker response. Adverse events (AEs) through week 52 were recorded.
Results
Thirty‐seven patients (10 UC and 27 CD) were included. All patients were anti‐TNF exposed, 34 (91.8%) had previously received > 2 biologic therapies and 8 (21.6%) had received dual advanced therapy. Upadacitinib was administered alongside vedolizumab ( n = 13, 35.1%); ustekinumab ( n = 14, 37.8%); risankizumab ( n = 9, 24.3%); infliximab ( n = 1, 2.7%); and golimumab ( n = 1, 2.7%). Median duration of combination therapy was 365 days (IQR 294,365). At weeks 8, 28, and 52, 12/17 (70.6%), 16/26 (61.5%), and 20/23 (87.0%) achieved clinical response and 6/17 (35.3%), 13/26 (50.0%), and 14/23 (60.9%) achieved clinical remission, respectively. Eighteen patients (48.6%) experienced AEs, and four patients (10.8%) had a serious AE requiring hospitalization.
Conclusions
In patients with highly refractory IBD, upadacitinib in combination with another biologic therapy can be effective with 60% achieving clinical remission at 52 weeks. Additional studies are needed to further assess the safety of upadacitinib combination therapy.
Zitieren
APA
Garcia, N. M., Mahadevan, U., Lewin, S., & Chugh, R. (2026). Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease. JCC Plus, 1(3). https://doi.org/10.1002/jcc5.70040
Vancouver
Garcia NM, Mahadevan U, Lewin S, Chugh R. Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease. JCC Plus. 2026;1(3). doi:10.1002/jcc5.70040
BibTeX
@article{Garcia2026,
author = {Garcia, Nicole M. and Mahadevan, Uma and Lewin, Sara and Chugh, Rishika},
title = {Real‐World Effectiveness and Safety of Upadacitinib in Combination With Biologic Therapy in Patients With Inflammatory Bowel Disease},
journal = {JCC Plus},
year = {2026},
volume = {1},
number = {3},
doi = {10.1002/jcc5.70040}
}
EUVIMED